Abstract
Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.
Keywords: HIV-1 integrase, human Pin1, protein – protein interaction, class II mutant.
Current Pharmaceutical Design
Title:HIV-1 Integrase Binding to its Cellular Partners: A Perspective from Computational Biology
Volume: 20 Issue: 21
Author(s): Vo Cam Quy, Vincenzo Carnevale, Lara Manganaro, Marina Lusic, Giulia Rossetti, Vanessa Leone, Cristina Fenollar-Ferrer, Simone Raugei, Giannino Del Sal, Mauro Giacca and Paolo Carloni
Affiliation:
Keywords: HIV-1 integrase, human Pin1, protein – protein interaction, class II mutant.
Abstract: Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.
Export Options
About this article
Cite this article as:
Quy Cam Vo, Carnevale Vincenzo, Manganaro Lara, Lusic Marina, Rossetti Giulia, Leone Vanessa, Fenollar-Ferrer Cristina, Raugei Simone, Sal Del Giannino, Giacca Mauro and Carloni Paolo, HIV-1 Integrase Binding to its Cellular Partners: A Perspective from Computational Biology, Current Pharmaceutical Design 2014; 20 (21) . https://dx.doi.org/10.2174/13816128113199990631
DOI https://dx.doi.org/10.2174/13816128113199990631 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radioprotective and Anticancer Efficacies of Ganoderma Lucidum in a
Mouse Tumor Model
Current Traditional Medicine Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Role of microRNAs in Osteoblasts Differentiation and Bone Disorders
Current Medicinal Chemistry Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology A Preliminary Study of the Action of Virtosomes from Non-dividing Cells on Tumour Cell Replication in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Oncoviruses and Head and Neck Cancer: An Impending Facts)
Recent Patents on Biomarkers Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics The Radio-Sensitizing Effect of Pharmacological Concentration of Ascorbic Acid on Human Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Dantrolene Potentiates the Antineoplastic Effect of Sorafenib in Hepatocellular Carcinoma via Targeting Ca<sup>+2</sup>/PI3K Signaling Pathway
Current Molecular Pharmacology